| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Crizotinib |
| Brand | Xalkori® |
| Indication | For the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC). |
| Assessment Process | |
| Rapid review commissioned | 06/02/2017 |
| Rapid review completed | 24/04/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Not Recommended. |
Latest NCPE Advice
Crovalimab (Piasky®). HTA ID: 24027
| Assessment Status | Rapid Review complete |
| HTA ID | 24027 |
| Drug | Crovalimab |
| Brand | Piasky® |
| Indication | For the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): (i) In patients with haemolysis with clinical symptom(s) indicative of high disease activity; (ii) In patients who are clinically stable after having been treated with a complement 5 inhibitor for at least the past 6 months |
| Assessment Process | |
| Rapid review commissioned | 11/07/2024 |
| Rapid review completed | 01/08/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that crovalimab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Cysteamine bitartrate delayed-release (Procysbi®)
| Assessment Status | NCPE Assessment process complete |
| HTA ID | - |
| Drug | Cysteamine bitartrate delayed-release |
| Brand | Procysbi® |
| Indication | For the treatment of proven nephropathic cystinosis. |
| Assessment Process | |
| Rapid review commissioned | 01/12/2015 |
| Rapid review completed | 15/12/2015 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at the submitted price |
| Full pharmacoeconomic assessment commissioned by HSE | 23/12/2015 |
| Pre-submission consultation with Applicant | 22/05/2017 |
| Full submission received from Applicant | 13/07/2017 |
| Preliminary review sent to Applicant | 22/08/2017 |
| NCPE assessment re-commenced | 29/08/2017 |
| Factual accuracy sent to Applicant | 17/10/2017 |
| NCPE assessment re-commenced | 15/11/2017 |
| NCPE assessment completed | 15/11/2017 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price |
The HSE has approved reimbursement following confidential price negotiations; July 2019
Dostarlimab (Jemperli®) in combination with carboplatin and paclitaxel. HTA ID: 24004
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24004 |
| Drug | Dostarlimab |
| Brand | Jemperli® |
| Indication | Dostarlimab is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 02/02/2024 |
| Rapid review completed | 09/02/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dostarlimab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/02/2024 |
| Pre-submission consultation with Applicant | 09/04/2024 |
| Full submission received from Applicant | 22/08/2024 |
| Preliminary review sent to Applicant | 14/05/2025 |
| NCPE assessment re-commenced | 26/06/2025 |
| Factual accuracy sent to Applicant | 11/08/2025 |
| NCPE assessment re-commenced | 18/08/2025 |
| NCPE assessment completed | 11/09/2025 |
| NCPE assessment outcome | The NCPE recommends that dostarlimab, in combination with carboplatin plus paclitaxel, for the first-line treatment of adult patients with dMMR/MSI-H primary advanced or recurrent EC, and who are candidates for systemic therapy, be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Dostarlimab (Jemperli®). HTA ID: 21045
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 21045 |
| Drug | Dostarlimab |
| Brand | Jemperli® |
| Indication | Indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. |
| Assessment Process | |
| Rapid review commissioned | 26/10/2021 |
| Rapid review completed | 30/11/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dostarlimab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 22/12/2021 |
| Full submission received from Applicant | 16/06/2022 |
| Preliminary review sent to Applicant | 22/11/2022 |
| NCPE assessment re-commenced | 20/12/2022 |
| Follow-up to preliminary review sent to Applicant | 08/02/2023 |
| NCPE assessment re-commenced | 10/02/2023 |
| Factual accuracy sent to Applicant | 27/02/2023 |
| NCPE assessment re-commenced | 10/03/2023 |
| NCPE assessment completed | 27/03/2023 |
| NCPE assessment outcome | The NCPE recommends that dostarlimab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Dupilumab (Dupixent®) for eosinophilic oesophagitis. HTA ID: 23047
| Assessment Status | Rapid Review Complete |
| HTA ID | 23047 |
| Drug | Dupilumab |
| Brand | Dupixent® |
| Indication | Dupilumab (Dupixent®) is indicated for the treatment of adults and adolescents 12 years and older, weighing at least 40 kg, with eosinophilic oesophagitis (EoE) who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. |
| Assessment Process | |
| Rapid review commissioned | 26/07/2023 |
| Rapid review completed | 07/09/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dupilumab for this indication compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
Dupilumab (Dupixent®) for prurigo nodularis. HTA ID: 23043
| Assessment Status | Rapid Review Complete |
| HTA ID | 23043 |
| Drug | Dupilumab |
| Brand | Dupixent® |
| Indication | Dupilumab (Dupixent®) is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 21/07/2023 |
| Rapid review completed | 24/08/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Dupilumab (Dupixent®) for severe asthma (children 6 to 11 years old). HTA ID: 23044
| Assessment Status | Rapid Review Complete |
| HTA ID | 23044 |
| Drug | Dupilumab |
| Brand | Dupixent® |
| Indication | Dupilumab (Dupixent®) is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. |
| Assessment Process | |
| Rapid review commissioned | 24/07/2023 |
| Rapid review completed | 05/09/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Elranatamab (Elrexfio®). HTA ID: 23066
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23066 |
| Drug | Elranatamab |
| Brand | Elrexfio® |
| Indication | Elranatamab (Elrexfio®) is indicated as monotherapy for the treatment of adult patients with relapsed, refractory multiple myeloma, who have received at least three prior therapies (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody) and have demonstrated disease progression on the last therapy. |
| Assessment Process | |
| Rapid review commissioned | 13/10/2023 |
| Rapid review completed | 29/11/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of elranatamab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/01/2024 |
| Pre-submission consultation with Applicant | 20/03/2024 |
| Full submission received from Applicant | 13/05/2024 |
| Preliminary review sent to Applicant | 14/02/2025 |
| NCPE assessment re-commenced | 19/03/2025 |
| Factual accuracy sent to Applicant | 13/06/2025 |
| NCPE assessment re-commenced | 17/06/2025 |
| NCPE assessment completed | 01/07/2025 |
| NCPE assessment outcome | The NCPE recommends that elranatamab (Elrexfio®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments* |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Enalapril maleate (Aqumeldi®). HTA ID: 24011
| Assessment Status | Rapid Review complete |
| HTA ID | 24011 |
| Drug | Enalapril maleate |
| Brand | Aqumeldi® |
| Indication | For the treatment of heart failure in children and adolescents from birth to less than 18 years of age. |
| Assessment Process | |
| Rapid review commissioned | 25/03/2024 |
| Rapid review completed | 12/04/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that enalapril maleate mini ODTs not be considered for reimbursement at the submitted price.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Eplontersen (Wainzua®) HTA ID: 24047
| Assessment Status | Rapid Review Complete |
| HTA ID | 24047 |
| Drug | Eplontersen |
| Brand | Wainzua® |
| Indication | Eplontersen (Wainzua®) is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy. |
| Assessment Process | |
| Rapid review commissioned | 15/11/2024 |
| Rapid review completed | 19/12/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that eplontersen not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Evolocumab (Repatha®). HTA ID: 25055
| Assessment Status | Rapid Review Complete |
| HTA ID | 25055 |
| Drug | Evolocumab |
| Brand | Repatha® |
| Indication | Evolocumab is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia. In this submission the Applicant is proposing to reduce the LDL-C thresholds specified in the current managed access protocol. The revised patient population includes: • adults with established atherosclerotic cardiovascular disease (i.e. confirmed diagnosis of myocardial infarction +/- revascularisation procedures, non-haemorrhagic stroke or peripheral arterial disease [i.e. secondary prevention] or in those who have undergone coronary artery bypass graft), with a LDL-C persistently ≥ 3.0 mmol/L and • adults with a confirmed diagnosis of heterozygous familial hypercholesterolaemia with a LDL-C persistently ≥ 2.5 mmol/L. |
| Assessment Process | |
| Rapid review commissioned | 28/08/2025 |
| Rapid review completed | 30/09/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that evolocumab not be considered for reimbursement at the submitted price*. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here
Faricimab (Vabysmo ®) for neovascular (wet) age-related macular degeneration. HTA ID: 22060
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22060 |
| Drug | Faricimab |
| Brand | Vabysmo ® |
| Indication | For the treatment of adult patients with neovascular (wet) age-related macular degeneration. |
| Assessment Process | |
| Rapid review commissioned | 29/08/2022 |
| Rapid review completed | 04/10/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of faricimab compared with the current standard of care.* |
| Full pharmacoeconomic assessment commissioned by HSE | 25/10/2022 |
| Pre-submission consultation with Applicant | 03/10/2023 |
| Full submission received from Applicant | 12/06/2024 |
| Preliminary review sent to Applicant | 19/03/2025 |
| NCPE assessment re-commenced | 16/04/2025 |
| Factual accuracy sent to Applicant | 27/05/2025 |
| NCPE assessment re-commenced | 05/06/2025 |
| NCPE assessment completed | 30/06/2025 |
| NCPE assessment outcome | The NCPE recommends that faricimab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
Faricimab (Vabysmo ®) for visual impairment due to diabetic macular oedema. HTA ID: 22061
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22061 |
| Drug | Faricimab |
| Brand | Vabysmo ® |
| Indication | For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO). |
| Assessment Process | |
| Rapid review commissioned | 29/08/2022 |
| Rapid review completed | 04/10/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of faricimab (Vabysmo®) for the treatment of DMO compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 25/10/2022 |
| Pre-submission consultation with Applicant | 03/10/2023 |
| Full submission received from Applicant | 12/06/2024 |
| Preliminary review sent to Applicant | 20/03/2025 |
| NCPE assessment re-commenced | 16/04/2025 |
| Factual accuracy sent to Applicant | 06/06/2025 |
| NCPE assessment re-commenced | 13/06/2025 |
| NCPE assessment completed | 01/07/2025 |
| NCPE assessment outcome | The NCPE recommends that faricimab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Finerenone (Kerendia®). HTA ID: 22012
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22012 |
| Drug | Finerenone |
| Brand | Kerendia® |
| Indication | For the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. |
| Assessment Process | |
| Rapid review commissioned | 21/02/2022 |
| Rapid review completed | 15/03/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of finerenone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/04/2022 |
| Pre-submission consultation with Applicant | 24/05/2022 |
| Full submission received from Applicant | 10/11/2022 |
| Preliminary review sent to Applicant | 24/02/2023 |
| NCPE assessment re-commenced | 29/03/2023 |
| Follow-up to preliminary review sent to Applicant | 08/05/2023 |
| NCPE assessment re-commenced | 18/05/2023 |
| Factual accuracy sent to Applicant | 12/06/2023 |
| NCPE assessment re-commenced | 04/07/2023 |
| NCPE assessment completed | 22/08/2023 |
| NCPE assessment outcome | The NCPE recommends that finerenone (Kerendia®) be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
Finerenone (Kerendia®). HTA ID: 23077
| Assessment Status | Rapid Review Complete |
| HTA ID | 23077 |
| Drug | Finerenone |
| Brand | Kerendia® |
| Indication | Finerenone (Kerendia®) is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes (T2D) in adults. |
| Assessment Process | |
| Rapid review commissioned | 20/12/2023 |
| Rapid review completed | 23/01/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that finerenone not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Glofitamab (Columvi®). HTA ID: 23055
| Assessment Status | Rapid Review Complete |
| HTA ID | 23055 |
| Drug | Glofitamab |
| Brand | Columvi® |
| Indication | Glofitamab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 30/08/2023 |
| Rapid review completed | 03/10/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of glofitamab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
Guselkumab (Tremfya®). HTA ID: 25050
| Assessment Status | Rapid Review Complete |
| HTA ID | 25050 |
| Drug | Guselkumab |
| Brand | Tremfya® |
| Indication | Guselkumab (Tremfya®) is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment. |
| Assessment Process | |
| Rapid review commissioned | 05/08/2025 |
| Rapid review completed | 11/09/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that guselkumab not be considered for reimbursement for this indication at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here
Guselkumab (Tremfya®). HTA ID: 25051
| Assessment Status | Rapid Review Complete |
| HTA ID | 25051 |
| Drug | Guselkumab |
| Brand | Tremfya® |
| Indication | Guselkumab (Tremfya®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biologic treatment. |
| Assessment Process | |
| Rapid review commissioned | 05/08/2025 |
| Rapid review completed | 11/09/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that guselkumab not be considered for reimbursement for this indication at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here
House dust mite allergen extract (Actair®). HTA ID: 23008
| Assessment Status | Rapid Review Complete |
| HTA ID | 23008 |
| Drug | House dust mite allergen extract |
| Brand | Actair® |
| Indication | Dermatophagoides pteronyssinus and Dermatophagoides farinae in equal parts (Actair®) is indicated for the treatment of moderate-to-severe house dust mite (HDM)–induced allergic rhinitis (AR) or rhinoconjunctivitis diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test [SPT] and/or specific immunoglobulin E [IgE]) in adolescents (aged 12-17 years) and adults. |
| Assessment Process | |
| Rapid review commissioned | 10/02/2023 |
| Rapid review completed | 24/02/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM allergen extracts compared with the current standard of care. |
Ibrutinib (Imbruvica®) for MCL
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ibrutinib |
| Brand | Imbruvica® |
| Indication | For the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL). |
| Assessment Process | |
| Rapid review commissioned | 07/11/2014 |
| Rapid review completed | 18/12/2014 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 10/04/2015 |
| NCPE assessment completed | 06/10/2015 |
| NCPE assessment outcome | Reimbursement not recommended. |
The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with relapsed or refractory MCL has not been demonstrated. Therefore it is not recommended for reimbursement at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.
Ibrutinib (Imbruvica®). HTA ID: 22054
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22054 |
| Drug | Ibrutinib |
| Brand | Imbruvica® |
| Indication | In combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia. |
| Assessment Process | |
| Rapid review commissioned | 27/07/2022 |
| Rapid review completed | 02/09/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ibrutinib in combination with venetoclax compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/09/2022 |
| Pre-submission consultation with Applicant | 14/11/2022 |
| Full submission received from Applicant | 14/02/2023 |
| Preliminary review sent to Applicant | 01/09/2023 |
| NCPE assessment re-commenced | 02/10/2023 |
| Factual accuracy sent to Applicant | 25/01/2024 |
| NCPE assessment re-commenced | 31/01/2024 |
| NCPE assessment completed | 09/02/2024 |
| NCPE assessment outcome | The NCPE recommends that ibrutinib (given in combination with venetoclax) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
Icosapent ethyl (Vazkepa®). HTA ID: 23006
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23006 |
| Drug | Icosapent ethyl |
| Brand | Vazkepa® |
| Indication | Icosapent ethyl (Vazkepa®) is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (?150 mg/dL [?1.7 mmol/L] and established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor. |
| Assessment Process | |
| Rapid review commissioned | 10/02/2023 |
| Rapid review completed | 10/03/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of icosapent ethyl compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/03/2023 |
| Pre-submission consultation with Applicant | 20/06/2023 |
| Full submission received from Applicant | 01/11/2023 |
| Preliminary review sent to Applicant | 18/09/2024 |
| NCPE assessment re-commenced | 25/10/2024 |
| Follow-up to preliminary review sent to Applicant | 22/01/2025 |
| NCPE assessment re-commenced | 30/01/2025 |
| Factual accuracy sent to Applicant | 04/03/2025 |
| NCPE assessment re-commenced | 12/03/2025 |
| NCPE assessment completed | 20/03/2025 |
| NCPE assessment outcome | The NCPE recommends that icosapent ethyl (Vazkepa®) be considered for reimbursement if cost effectiveness can be improved relative to existing treatments and that a Managed Access Programme is introduced*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Idelalisib (Zydelig®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Idelalisib |
| Brand | Zydelig® |
| Indication | In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. |
| Assessment Process | |
| Rapid review commissioned | 08/12/2014 |
| Rapid review completed | 30/12/2014 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 04/06/2015 |
| NCPE assessment completed | 16/02/2016 |
| NCPE assessment outcome | Reimbursement not recommended. |
The HSE has approved reimbursement following confidential price negotiations December 2016.
Imlifidase (Idefirix®). HTA ID: 23041
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23041 |
| Drug | Imlifidase |
| Brand | Idefirix® |
| Indication | For desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of imlifidase should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients. |
| Assessment Process | |
| Rapid review commissioned | 19/07/2023 |
| Rapid review completed | 01/08/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of imlifidase compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 30/08/2023 |
| Pre-submission consultation with Applicant | 21/11/2023 |
| Full submission received from Applicant | 22/04/2024 |
| Preliminary review sent to Applicant | 16/09/2024 |
| NCPE assessment re-commenced | 09/10/2024 |
| Factual accuracy sent to Applicant | 21/11/2024 |
| NCPE assessment re-commenced | 28/11/2024 |
| NCPE assessment completed | 28/11/2024 |
| NCPE assessment outcome | The NCPE recommends that imlifidase be considered for reimbursement*. |
*This recommendation should be considered while also having regards to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Inavolisib (Itovebi®). HTA ID: 25056
| Assessment Status | Pre-submission consultation scheduled |
| HTA ID | 25056 |
| Drug | Inavolisib |
| Brand | Itovebi® |
| Indication | Inavolisib, in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. |
| Assessment Process | |
| Rapid review commissioned | 02/09/2025 |
| Rapid review completed | 06/10/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of inavolisib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/10/2025 |
Inclisiran (Leqvio®). HTA ID: 20051
| Assessment Status | Assessment process complete |
| HTA ID | 20051 |
| Drug | Inclisiran |
| Brand | Leqvio® |
| Indication | For the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adult patients, as an adjunct to diet (a) in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach low density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or (b) alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. |
| Assessment Process | |
| Rapid review commissioned | 23/11/2020 |
| Rapid review completed | 16/12/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of inclisiran compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 06/01/2021 |
| Pre-submission consultation with Applicant | 22/02/2021 |
| Full submission received from Applicant | 23/07/2021 |
| Preliminary review sent to Applicant | 19/10/2021 |
| NCPE assessment re-commenced | 16/11/2021 |
| Factual accuracy sent to Applicant | 16/02/2022 |
| NCPE assessment re-commenced | 23/02/2022 |
| NCPE assessment completed | 23/03/2022 |
| NCPE assessment outcome | The NCPE recommends that inclisiran (Leqvio®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Indacterol/glycopyrronium/mometasone furoate (Enerzair®). HTA ID: 20023
| Assessment Status | Rapid Review Complete |
| HTA ID | 20023 |
| Drug | Indacterol/glycopyrronium/mometasone furoate |
| Brand | Enerzair® |
| Indication | As a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting β2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year. |
| Assessment Process | |
| Rapid review commissioned | 13/05/2020 |
| Rapid review completed | 10/06/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that indacterol/glycopyrronium/mometasone furoate (Enerzair®) be considered for reimbursement* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement; November 2020
Indacterol/mometasone furoate (Atectura®). HTA ID: 20024
| Assessment Status | Rapid Review Complete |
| HTA ID | 20024 |
| Drug | Indacterol/mometasone furoate |
| Brand | Atectura® |
| Indication | As maintenance treatment of asthma in adults and adolescents 12 years and older not adequately controlled with inhaled corticosteroids and inhaled short acting β2 agonists. |
| Assessment Process | |
| Rapid review commissioned | 13/05/2020 |
| Rapid review completed | 10/06/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Indacterol/mometasone furoate (Atectura®) be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
Infliximab (Inflectra®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Infliximab |
| Brand | Inflectra® |
| Indication | For the treatment of Rheumatoid Arthritis, Adult Crohn’s disease, Paediatric Crohn’s disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis. |
| Assessment Process | |
| Rapid review commissioned | 10/09/2013 |
| Rapid review completed | 20/09/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Infliximab (Remsima SC®). HTA ID: 20012
| Assessment Status | Rapid Review Complete |
| HTA ID | 20012 |
| Drug | Infliximab |
| Brand | Remsima SC® |
| Indication | In combination with methotrexate, is indicated in rheumatoid arthritis for the reduction of signs and symptoms as well as the improvement in physical function in: adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs. |
| Assessment Process | |
| Rapid review commissioned | 04/03/2020 |
| Rapid review completed | 24/03/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that infliximab SC not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
Infliximab (Remsima® SC). HTA ID: 20042
| Assessment Status | Rapid Review Complete |
| HTA ID | 20042 |
| Drug | Infliximab |
| Brand | Remsima® SC |
| Indication | For treatment of adult patients with Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis in line with the adult indications of the IV formulation. |
| Assessment Process | |
| Rapid review commissioned | 23/09/2020 |
| Rapid review completed | 15/10/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Remsima SC not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations March 2022.
Infliximab (Remsima®) for Crohn’s disease dose escalation. HTA ID: 25022
| Assessment Status | Rapid Review Complete |
| HTA ID | 25022 |
| Drug | Infliximab |
| Brand | Remsima® |
| Indication | Infliximab (Remsima®) is indicated for the treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. It is also indicated for treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy). |
| Assessment Process | |
| Rapid review commissioned | 18/03/2025 |
| Rapid review completed | 11/04/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that infliximab (Remsima®), for Crohn’s disease dose escalation, not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Ingenol mebutate gel (Picato®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ingenol mebutate |
| Brand | Picato® |
| Indication | For cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (AK) in adults. |
| Assessment Process | |
| Rapid review commissioned | 12/11/2012 |
| Rapid review completed | 30/11/2012 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Inhaled insulin (Exubera®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Inhaled insulin |
| Brand | Exubera® |
| Indication | Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera®) versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. |
| Assessment Process | |
| Full pharmacoeconomic assessment commissioned by HSE | 01/04/2006 |
| NCPE assessment completed | 01/06/2006 |
Inotersen (Tegsedi®). HTA ID: 19034
| Assessment Status | Assessment process complete |
| HTA ID | 19034 |
| Drug | Inotersen |
| Brand | Tegsedi® |
| Indication | For the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin (TTR) amyloidosis (hATTR). |
| Assessment Process | |
| Rapid review commissioned | 26/08/2019 |
| Rapid review completed | 07/10/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of inotersen compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 09/10/2019 |
| Pre-submission consultation with Applicant | 08/12/2020 |
| Full submission received from Applicant | 23/07/2021 |
| Preliminary review sent to Applicant | 05/10/2021 |
| NCPE assessment re-commenced | 02/11/2021 |
| Factual accuracy sent to Applicant | 22/12/2021 |
| NCPE assessment re-commenced | 10/01/2022 |
| NCPE assessment completed | 11/02/2022 |
| NCPE assessment outcome | The NCPE recommends that inotersen be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations – August 2022.
Inotuzumab ozogamicin (Besponsa®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Inotuzumab ozogamicin |
| Brand | Besponsa® |
| Indication | As monotherapy for the treatment of adults with relapsed or refractory (R/R) CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI). |
| Assessment Process | |
| Rapid review commissioned | 03/07/2017 |
| Rapid review completed | 08/09/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 11/09/2017 |
| Pre-submission consultation with Applicant | 02/10/2017 |
| Full submission received from Applicant | 08/03/2018 |
| Preliminary review sent to Applicant | 13/07/2018 |
| NCPE assessment re-commenced | 02/08/2018 |
| Factual accuracy sent to Applicant | 31/08/2018 |
| NCPE assessment re-commenced | 07/09/2018 |
| NCPE assessment completed | 14/09/2018 |
| NCPE assessment outcome | The NCPE recommends that inotuzumab should be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations; May 2019
Insulin aspart (Fiasp®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Insulin aspart |
| Brand | Fiasp® |
| Indication | For the treatment of diabetes mellitus in adults. |
| Assessment Process | |
| Rapid review commissioned | 17/05/2017 |
| Rapid review completed | 14/06/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Insulin aspart (NovoRapid® FlexTouch ®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Insulin aspart |
| Brand | NovoRapid® FlexTouch ® |
| Indication | For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. |
| Assessment Process | |
| Rapid review commissioned | 22/07/2014 |
| Rapid review completed | 28/08/2014 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at the submitted price. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
Insulin Degludec (Tresiba®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Insulin Degludec |
| Brand | Tresiba® |
| Indication | Treatment of diabetes mellitus |
| Assessment Process | |
| Rapid review commissioned | 17/12/2012 |
| Rapid review completed | 04/01/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 04/11/2014 |
| NCPE assessment completed | 04/05/2015 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
December 2015
The HSE has approved reimbursement following confidential price negotiations.
Insulin degludec/liraglutide (IDegLira) (Xultophy®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Insulin degludec/liraglutide (IDegLira) |
| Brand | Xultophy® |
| Indication | For the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control. |
| Assessment Process | |
| Rapid review commissioned | 19/09/2016 |
| Rapid review completed | 17/10/2016 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at the submitted price. |
The HSE has approved reimbursement; July 2019.
Insulin Glargine (Abasaglar®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Insulin Glargine |
| Brand | Abasaglar® |
| Indication | For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. |
| Assessment Process | |
| Rapid review commissioned | 04/09/2015 |
| Rapid review completed | 12/10/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Insulin Glargine U300 (Toujeo®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Insulin Glargine U300 |
| Brand | Toujeo® |
| Indication | for the treatment of diabetes mellitus in adults. |
| Assessment Process | |
| Rapid review commissioned | 14/05/2015 |
| Rapid review completed | 02/07/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended at the Submitted Price |
The HSE has approved reimbursement following confidential price negotiations.
Ipilimumab (Yervoy®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ipilimumab |
| Brand | Yervoy® |
| Indication | For the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy. |
| Assessment Process | |
| Rapid review commissioned | 31/05/2011 |
| Rapid review completed | 09/06/2011 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/07/2011 |
| NCPE assessment completed | 02/09/2011 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
September 2013
The HSE has approved reimbursement following confidential price negotiations.
Iptacopan (Fabhalta®). HTA ID: 24023
| Assessment Status | Rapid Review Complete |
| HTA ID | 24023 |
| Drug | Iptacopan |
| Brand | Fabhalta® |
| Indication | Iptacopan is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. |
| Assessment Process | |
| Rapid review commissioned | 04/06/2024 |
| Rapid review completed | 16/07/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical and cost effectiveness of iptacopan compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
Iron (III) isomaltoside 1000 (Diafer®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Iron (III) isomaltoside 1000 |
| Brand | Diafer® |
| Indication | For the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used. |
| Assessment Process | |
| Rapid review commissioned | 10/10/2015 |
| Rapid review completed | 18/11/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Iron (III) isomaltoside 1000 (Monover®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Iron (III) isomaltoside 1000 |
| Brand | Monover® |
| Indication | For the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly. |
| Assessment Process | |
| Rapid review commissioned | 10/10/2015 |
| Rapid review completed | 18/11/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Iron isomaltoside 1000 (MonoVer®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Iron isomaltoside 1000 |
| Brand | MonoVer® |
| Indication | For the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly. |
| Assessment Process | |
| Rapid review commissioned | 10/01/2011 |
| Rapid review completed | 02/02/2011 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone. HTA ID: 23024
| Assessment Status | Rapid Review Complete |
| HTA ID | 23024 |
| Drug | Isatuximab |
| Brand | Sarclisa® |
| Indication | Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone, is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
| Assessment Process | |
| Rapid review commissioned | 09/05/2023 |
| Rapid review completed | 25/05/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of isatuximab in combination with carfilzomib and dexamethasone compared with the current standard of care. |
Isavuconazole (Cresemba®) for the treatment of invasive aspergillosis.
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Isavuconazole |
| Brand | Cresemba® |
| Indication | For the treatment of invasive aspergillosis |
| Assessment Process | |
| Rapid review commissioned | 11/04/2016 |
| Rapid review completed | 11/05/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended at the submitted price |
The HSE has approved reimbursement following confidential price negotiations: April 2018.